PFCS
CRBP icon

Pale Fire Capital SE’s Corbus Pharmaceuticals CRBP Stock Holding History

Pale Fire Capital SE’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$228K Buy
24,301
+2,951
+14% +$27.9K 0.02% 62
2026
Q1 		$200K Buy
21,350
+2,700
+14% +$22.7K 0.02% 54
2025
Q4 		$152K Buy
+18,650
New +$230K 0.01% 57

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Pale Fire Capital SE's CRBP Position: Q2 2026 in Review

Pale Fire Capital SE increased its Corbus Pharmaceuticals (CRBP) stake by 14% in Q2 2026, buying an estimated $27.9K and bringing the position to 24,301 shares worth $228K. The position accounts for 0.02% of the portfolio, ranked #62.

Pale Fire Capital SE first reported a position in CRBP in Q4 2025 and has held it in 3 quarters since. 107 funds tracked by Wall St. Rank hold CRBP as of Q2 2026.

  • Pale Fire Capital SE held 24,301 shares of Corbus Pharmaceuticals worth $228K as of Q2 2026.
  • Pale Fire Capital SE bought 2,951 Corbus Pharmaceuticals shares in Q2 2026, an estimated $27.9K.
  • Corbus Pharmaceuticals made up 0.02% of Pale Fire Capital SE's portfolio in Q2 2026, its #62 holding.
  • Pale Fire Capital SE first reported a position in Corbus Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2026.

Based on Pale Fire Capital SE's 13F filing for Q2 2026, filed 13 Aug 2026.